Takashi Nakada

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara et al. · Clinical Cancer Research · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +13

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai et al. · Clinical Cancer Research · 2019 · 174 citations

Medicine, Oncology, Pharmacology +15

Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads

Takashi Nakada, Takeshi Masuda, Hiroyuki Naito et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 169 citations

Pharmacy, Medicinal Chemistry, Pharmaceutics +14

Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology

Yusuke Ogitani, Yuki Abe, Takuma Iguchi et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 51 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody–Drug Conjugate

Kenji Iida, Amr H. Abdelhamid Ahmed, Akiko Kawano Nagatsuma et al. · Cancer Discovery · 2021 · 50 citations

Medicine, Oncology, Pharmacology +17